Gilead Sciences (NASDAQ:GILD) perks up 1% premarket on light volume on the heels of a statement from
Japan’s Prime Minister Shinzo Abe that health authorities intend to
approve antiviral remdesivir next month for the treatment of COVID-19.
Once the company files its application, the
Japanese government is set to fast track review and approval. A clinical
trial there should wind up in this week.
https://seekingalpha.com/news/3564630-japan-on-board-gileads-remdesivir-approval-expected-in-may
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.